argenx SE (ARGX) Stock Price & How to Invest

Last updated November 2026

Short answer

argenx (ARGX) is a commercial-stage immunology company whose FcRn blocker Vyvgart (efgartigimod) is driving rapid sales growth across autoimmune indications, so it trades as a high-multiple biotech growth story rather than a value or dividend name. Exposure is usually taken by buying the Nasdaq-listed ADR directly or through biotech and healthcare funds that hold it. As of October 16, 2026 the ADR closed at $817.80, a market value of ~$51.4 billion, after falling ~17% in a month that included a failed Phase 3 study in Sjogren's disease.

ARGX stock price

As of 2026-11-16, argenx SE (ARGX) last closed at $950.95, up 2.3% over the past year. Over the past 52 weeks it has traded between $663.93 and $1,058.90.

ARGX last close
$950.95
1 day
-0.95%
1 month
+16.09%
1 year
+2.30%
52-week range
$663.93 to $1,058.90
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or argenx SE's investor relations page. Walnut is informational, not investment advice.

ARGX key stats

At $950.95 on November 16, 2026, argenx SE (ARGX) has a market cap of $59.8B and a P/E of 32.9 on trailing earnings (28.6 on forward earnings).

Market cap
$59.8B
P/E (trailing)
32.9
P/E (forward)
28.6
EPS (trailing 12 months)
$28.87
Price to book
176.6

Market cap, P/E and yield are measured at the $950.95 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with argenx SE (ARGX)?

The last two weeks for argenx SE, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • ARGX closed at $950.95 on November 16, 2026, down 1.2% over the past five trading days (from $962.27).
  • On November 9, 2026, argenx SE filed a current report (6-K) with the SEC. Read the 6-K on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does argenx SE (ARGX) do?

argenx SE is a Netherlands-based, globally operating immunology company that trades in the US as a Nasdaq ADR. Its lead product, Vyvgart and the subcutaneous Vyvgart Hytrulo (efgartigimod), is an FcRn blocker that lowers pathogenic IgG antibodies. It is approved for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), plus primary immune thrombocytopenia in Japan, and reached roughly 19,000 patients on treatment by the end of 2025.

The investment picture is a classic biotech growth profile: revenue is compounding quickly (about $4.15 billion in 2025 global product net sales, up roughly 90% year over year, then ~$1.31 billion in Q1 2026 and ~$1.54 billion in Q2 2026, up ~59% year over year), the company is solidly profitable (trailing net income ~$1.72 billion) and holds ~$5.2 billion of cash against minimal debt, and the pipeline aims to expand efgartigimod into new autoimmune indications while advancing next-generation FcRn and complement candidates. Q2 2026 EPS of $7.32 beat a $6.19 consensus, the fourth straight beat. The setback came on October 9, 2026, when argenx stopped its Phase 3 UNITY study of subcutaneous efgartigimod in Sjogren's disease after an independent data monitoring committee found it could not meet its primary endpoint, and the shares fell ~12% that day. In early October Halozyme also expanded its ENHANZE license with argenx to two more exclusive targets. At $817.80 on October 16, 2026, ARGX is down ~2.6% year to date and ~17% over a month, trading at ~31x trailing and ~23x forward earnings with a ~$51.4 billion market cap, so the shares still carry the volatility typical of a single-franchise-led biotech. Third-quarter results are scheduled for October 22, 2026, with consensus revenue near $1.63 billion.

What's driving argenx SE (ARGX)?

1. Vyvgart franchise momentum

Vyvgart posted its 17th consecutive quarter of growth in Q1 2026, with sales near $1.3 billion (up 63% year over year) and roughly 19,000 patients on treatment. Uptake of the subcutaneous Hytrulo formulation and continued gMG and CIDP adoption are the core revenue engine. Each new label and geography adds to a still-expanding addressable base. Second-quarter 2026 revenue reached ~$1.54 billion, up ~59% year over year, extending the run.

2. Label and indication expansion

argenx is pursuing efgartigimod in seronegative gMG, ocular myasthenia gravis, primary ITP, Graves' disease and myositis. A widening set of approved uses could turn a single molecule into a multi-indication franchise, but not every expansion will succeed: in October 2026 the Phase 3 UNITY trial in Sjogren's disease was stopped for futility after an interim analysis, removing one of the larger planned indications. Regulatory decisions and Phase 3 readouts in the remaining indications are the near-term swing factors.

3. Deep autoimmune pipeline

Beyond efgartigimod, argenx is advancing next-generation FcRn candidates (such as ARGX-213 and ARGX-124) and first-in-class assets including empasiprubart (a C2 complement inhibitor) and adimanebart. Its Vision 2030 framework targets 10 labeled indications and five pipeline candidates in Phase 3. This breadth is what supports the long-duration growth narrative. In October 2026 argenx added two more exclusive targets to its ENHANZE subcutaneous-delivery license with Halozyme, which earns milestones and royalties on products that use it.

4. Profitability and balance sheet

argenx has crossed into sustained profitability, reporting Q1 2026 profit of about $366 million (up 116% year over year) and Q2 2026 profit of ~$472 million, with adjusted EPS of $5.52 and $7.32 that beat consensus both times. Trailing net income is ~$1.72 billion and cash stood at ~$5.2 billion against ~$47 million of debt at mid-year. That cushion funds pipeline investment without near-term dependence on capital markets.

What are the risks to argenx SE (ARGX)?

argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. The FcRn field is crowding: UCB (rozanolixizumab, zilucoplan), Johnson & Johnson (nipocalimab), and Immunovant (batoclimab and IMVT-1402) are all competing in overlapping indications, and AstraZeneca's complement inhibitors address parts of the same market. Pipeline setbacks can sharply reset expectations given the valuation: the October 2026 futility stop of the Phase 3 UNITY trial in Sjogren's disease sent the shares down ~12% in a day and ~17% over the month. As an ADR of a European company, holders also carry currency and cross-listing considerations. Biotech shares like ARGX tend to be volatile around clinical and regulatory events.

What is the argenx SE (ARGX) forecast?

23 analysts publish price targets on ARGX, averaging $1147.35 as of November 2026, or +20.7% against the $950.95 share price on November 16, 2026. The published targets run from $861.00 to $1353.00, a moderate spread, and the ratings split 20 buy, 3 hold, 0 sell. Over the last six months there have been 4 raises and 7 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ARGX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is ARGX a buy or a sell?

We give no verdict on argenx SE. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Vyvgart franchise momentum. Vyvgart posted its 17th consecutive quarter of growth in Q1 2026, with sales near $1.3 billion (up 63% year over year) and roughly 19,000 patients on treatment. The most optimistic published target, $1353.00, assumes this works close to its best case.

The case against. argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. The most pessimistic target, $861.00, is roughly what ARGX is worth if this bites instead.

Read the full bull and bear case on ARGX, including what would have to change to break either one. Walnut is not an investment adviser.

Has argenx SE (ARGX) split its stock?

No. argenx SE (ARGX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is argenx SE (ARGX) valued?

Market cap, P/E and dividend yield at today's price are in the ARGX key stats above. The business figures below come from argenx SE's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$5.32B; Q2 2026 ~$1.54B, up ~59% year over year
  • Q2 2026 EPS: $7.32 vs $6.19 consensus; profit ~$472M
  • Net income (TTM): ~$1.72B; net margin ~32%
  • Cash and debt: ~$5.2B cash, ~$47M debt
  • Dividend: None

As of October 2026: At ~31x trailing and ~23x forward earnings, argenx is valued as a profitable growth company rather than a speculative biotech, with consensus expecting revenue of ~$6.3 billion in 2026 and ~$7.76 billion in 2027. The Sjogren's failure trimmed some pipeline value from the price, and the mean analyst target of ~$1,153 across 23 analysts sits well above the $817.80 close. Third-quarter results on October 22, 2026 (consensus revenue ~$1.63 billion) are the next check on Vyvgart growth.

Which ETFs hold argenx SE (ARGX)?

If you want ARGX exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

ETFName% in ARGXExpense ratio
BBHVanEck Biotech ETF4.6%0.35%
IBBiShares Biotechnology ETF3.74%0.44%

What themes does argenx SE (ARGX) fit?

These are the investment theses ARGX naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Who competes with argenx SE (ARGX)?

FcRn blocker rivals

UCB markets rozanolixizumab (Rystiggo) and zilucoplan (Zilbrysq) in myasthenia gravis, Johnson & Johnson has nipocalimab (Imaavy) approved in gMG, and Immunovant is developing batoclimab and the next-generation IMVT-1402. These directly target the same FcRn mechanism and overlapping autoimmune indications as efgartigimod.

Other autoimmune and complement players

AstraZeneca (via its Alexion complement franchise, Soliris and Ultomiris) competes in myasthenia gravis and related neuromuscular diseases through a different mechanism. Broader immunology and rare-disease developers pursuing IgG-lowering and complement approaches round out the competitive set.

What stocks are similar to argenx SE (ARGX)?

Other names that sit close to ARGX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in argenx SE (ARGX)

There are three common ways to get ARGX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (BBH, IBB), which spreads the position across many companies. Or build it into a focused thematic portfolio, so ARGX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ARGX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on argenx SE (ARGX)

argenx is a fast-growing FcRn-focused immunology company where the investment case rests on Vyvgart uptake and pipeline expansion against a rich valuation. The October 2026 futility stop of the Phase 3 UNITY trial in Sjogren's disease was a reminder that not every new indication will work, even as second-quarter sales grew ~59% and beat estimates.

More on argenx SE (ARGX)

Whether ARGX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ARGX a buy or a sell?, and where the stock could go from here in the ARGX stock forecast.

For income investors, whether ARGX pays a dividend and how the payout looks is covered in does ARGX pay a dividend? And to weigh ARGX against a peer, read the full side-by-side comparisons: ARGX vs VRTX and ARGX vs REGN.

Wondering how ARGX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about argenx SE

Ask Walnut's AI anything about ARGX and see how it fits what you own.

FAQ

What does argenx do?

+

argenx is an immunology company focused on autoimmune diseases. Its lead product, Vyvgart (efgartigimod), is an FcRn blocker that lowers harmful IgG antibodies, and it is approved for conditions including generalized myasthenia gravis and CIDP.

What is Vyvgart and why does it matter to ARGX?

+

Vyvgart, and its subcutaneous version Vyvgart Hytrulo, is efgartigimod, the drug behind nearly all of argenx's revenue. Its adoption in myasthenia gravis and CIDP drove roughly $4.15 billion in 2025 net sales, so Vyvgart uptake is the primary driver of the stock.

Is ARGX profitable?

+

Yes. argenx reported profit of about $366 million in the first quarter of 2026 and ~$472 million in the second, for trailing net income of ~$1.72 billion, and held roughly $5.2 billion in cash against minimal debt at mid-2026. That is a clear break from the cash-burning profile typical of development-stage biotech.

How fast is argenx growing?

+

Growth has been rapid. Global product net sales rose about 90% year over year in 2025 to roughly $4.15 billion, and Q1 2026 sales of about $1.3 billion were up 63% from a year earlier, marking the 17th consecutive quarter of Vyvgart growth. Q2 2026 revenue then rose to ~$1.54 billion, up ~59% year over year.

Who competes with argenx?

+

In the FcRn space, UCB (rozanolixizumab), Johnson & Johnson (nipocalimab), and Immunovant (batoclimab and IMVT-1402) are direct rivals. AstraZeneca's Alexion complement inhibitors compete in overlapping neuromuscular conditions through a different mechanism.

What are the main risks with ARGX?

+

Revenue is concentrated in one molecule, efgartigimod, so safety, pricing, or uptake issues would hit the whole business. The FcRn field is crowding, pipeline or regulatory setbacks could reset a high valuation, and biotech shares are volatile around clinical events. The October 2026 futility stop of the Phase 3 Sjogren's disease trial showed how quickly a single readout can move the shares.

How can I invest in argenx?

+

argenx trades on the Nasdaq as an ADR under the ticker ARGX, so US investors can buy the shares directly through a brokerage. It is also held by many biotech and healthcare sector funds, which offer diversified exposure.

Is ARGX a good investment?

+

That depends on your goals, time horizon, and risk tolerance, and Walnut is not an investment adviser. As of October 16, 2026, the ADR is $817.80, ~31x trailing earnings. argenx offers fast growth and an expanding pipeline but carries single-franchise concentration, competition, and a rich valuation, so review the business and figures yourself or with a licensed professional.

How did argenx do in its latest quarter?

+

In the second quarter of 2026 (ended June 30), argenx reported revenue of ~$1.54 billion, up ~59% year over year, and profit of ~$472 million. EPS of $7.32 beat the $6.19 consensus, its fourth consecutive beat. Third-quarter results are scheduled for October 22, 2026, with consensus revenue near $1.63 billion.

What happened to argenx's Sjogren's disease trial?

+

On October 9, 2026, argenx stopped its Phase 3 UNITY study of subcutaneous efgartigimod in adults with moderate-to-severe Sjogren's disease after an independent data monitoring committee concluded at an interim analysis that the trial could not meet its primary endpoint. The shares fell ~12% on the news. The decision does not affect approved uses in gMG and CIDP.

How has ARGX stock performed in 2026?

+

As of the October 16, 2026 close of $817.80, ARGX is down ~2.6% year to date and ~2.3% over the past year, after a ~17% drop in the past month, within a 52-week range of ~$662 to ~$1,073. Walnut is not an investment adviser, and past performance does not predict future returns.

Guides that feature ARGX

ARGX is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with argenx SE's investor relations page or your broker before making investment decisions.